VP22 enhances antibody responses from DNA vaccines but not by intercellular spread

Vaccine

Volumn 23, Issue 16, 2005, Pages 1931-1940

  Perkins, Stuart D ^a   Hartley, M Gill ^a   Lukaszewski, Roman A ^a   Phillpotts, Robert J ^a   Stevenson, Freda K ^b   Bennett, Alice M ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

DNA vaccine; GFP; Intercellular spread; Protein transduction domain; VP22

Indexed keywords

DNA VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; PROTEIN VP22; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DNA VECTOR; EXPRESSION VECTOR; GENE AMPLIFICATION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS GENE;

EID: 14244255427     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.10.033     Document Type: Article

References (53)

1. J.J. Donnelly, J.B. Ulmer, J.W. Shiver, and M.A. Liu DNA vaccines Annu Rev Immunol 15 1997 617 648
2. S. Calarota, G. Bratt, S. Nordlund, J. Hinkula, A.C. Leandersson, and E. Sandstrom Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients Lancet 351 9112 1998 1320 1325
3. R. Wang, D.L. Doolan, T.P. Le, R.C. Hedstrom, K.M. Coonan, and Y. Charoenvit Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine Science 282 5388 1998 476 480
4. R.R. MacGregor, J.D. Boyer, K.E. Ugen, K.E. Lacy, S.J. Gluckman, and M.L. Bagarazzi First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response J Infect Dis 178 1 1998 92 100
5. A.H. Lee, Y.S. Suh, J.H. Sung, S.H. Yang, and Y.C. Sung Comparison of various expression plasmids for the induction of immune response by DNA immunization Mol Cells 7 4 1997 495 501
6. M. Kwissa, K. von Kampen, R. Zurbriggen, R. Gluck, J. Reimann, and R. Schirmbeck Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control Vaccine 18 22 2000 2337 2344
7. R.J. Bartlett, S.L. Secore, J.T. Singer, M. Bodo, K. Sharma, and C. Ricordi Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo Cell Transplant 5 3 1996 411 419
8. L. Deml, A. Bojak, S. Steck, M. Graf, J. Wild, and R. Schirmbeck Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein J Virol 75 22 2001 10991 11001
9. L. Vinner, H.V. Nielsen, K. Bryder, S. Corbet, C. Nielsen, and A. Fomsgaard Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons Vaccine 17 17 1999 2166 2175
10. E.T. Marques Jr., P. Chikhlikar, L.B. De Arruda, I.C. Leao, Y. Lu, and J. Wong HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 (LAMP-1) as a DNA plasmid vaccine chimera is highly expressed, traffics to MHC II compartment, and elicits enhanced immune responses J Biol Chem 2003
11. V.W. Bramwell, J.E. Eyles, S. Somavarapu, and H.O. Alpar Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen Immunology 106 3 2002 412 418
12. S. Babiuk, M.E. Baca-Estrada, M. Foldvari, M. Storms, D. Rabussay, and G. Widera Electroporation improves the efficacy of DNA vaccines in large animals Vaccine 20 27-28 2002 3399 3408
13. D. Zhu, J. Rice, N. Savelyeva, and F.K. Stevenson DNA fusion vaccines against B-cell tumors Trends Mol Med 7 12 2001 566 572
14. C.A. King, M.B. Spellerberg, D. Zhu, J. Rice, S.S. Sahota, and A.R. Thompsett DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma Nat Med 4 11 1998 1281 1286
15. G.D. Elliott, and D.M. Meredith The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49 J Gen Virol 73 Pt 3 1992 723 726
16. G. Elliott, and P. O'Hare Intercellular trafficking and protein delivery by a herpesvirus structural protein Cell 88 2 1997 223 233
17. M.S. Dilber, A. Phelan, A. Aints, A.J. Mohamed, G. Elliott, and C.I. Smith Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22 Gene Ther 6 1 1999 12 21
18. A. Phelan, G. Elliott, and P. O'Hare Intercellular delivery of functional p53 by the herpesvirus protein VP22 Nat Biotechnol 16 5 1998 440 443
19. K.N. Wills, I.A. Atencio, J.B. Avanzini, S. Neuteboom, A. Phelan, and J. Philopena Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus J Virol 75 18 2001 8733 8741
20. L. Zender, R. Kock, M. Eckhard, B. Frericks, T. Gosling, and T. Gebhardt Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors Gastroenterology 123 2 2002 608 618
21. Z. Lai, and R.O. Brady Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector J Neurosci Res 67 3 2002 363 371
22. W.F. Cheng, C.H. Hung, C.Y. Chai, K.F. Hsu, L. He, and M. Ling Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen J Virol 75 5 2001 2368 2376
23. W.F. Cheng, C.F. Hung, K.F. Hsu, C.Y. Chai, L. He, and J.M. Polo Cancer immunotherapy using sindbis virus replicon particles encoding a vp22 - antigen fusion Hum Gene Ther 13 4 2002 553 568
24. C.F. Hung, W.F. Cheng, C.Y. Chai, K.F. Hsu, L. He, and M. Ling Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen J Immunol 166 9 2001 5733 5740
25. N. Michel, W. Osen, L. Gissmann, T.N. Schumacher, H. Zentgraf, and M. Muller Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination Virology 294 1 2002 47 59
26. W. Derer, H.P. Easwaran, C.W. Knopf, H. Leonhardt, and M.C. Cardoso Direct protein transfer to terminally differentiated muscle cells J Mol Med 77 8 1999 609 613
27. W. Derer, H.P. Easwaran, H. Leonhardt, and M.C. Cardoso A novel approach to induce cell cycle reentry in terminally differentiated muscle cells Faseb J 16 1 2002 132 133
28. C.S. Liu, B. Kong, H.H. Xia, K.A. Ellem, and M.Q. Wei VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death J Gene Med 3 2 2001 145 152
29. S.J. Morris, H. Smith, and C. Sweet Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role Arch Virol 147 5 2002 961 979
30. J. Soden, A. Stevens, and D.W. Ray Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation J Endocrinol 172 3 2002 615 625
31. W.A. Wybranietz, F. Prinz, M. Spiegel, A. Schenk, M. Bitzer, and M. Gregor Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines J Gene Med 1 4 1999 265 274
32. L. Zender, F. Kuhnel, R. Kock, M. Manns, and S. Kubicka VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo Cancer Gene Ther 9 6 2002 489 496
33. M. Lundberg, and M. Johansson Is VP22 nuclear homing an artifact? Nat Biotechnol 19 8 2001 713 774
34. G. Elliott, and P. O'Hare Intercellular trafficking of VP22-GFP fusion proteins Gene Ther 6 1 1999 149 151
35. A. Aints, M.S. Dilber, and C.I. Smith Intercellular spread of GFP-VP22 J Gene Med 1 4 1999 275 279
36. R.P. Bennett, and B. Dalby Protein delivery using VP22 Nat Biotechnol 20 1 2002 20
37. P.O. Falnes, J. Wesche, and S. Olsnes Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment Biochemistry 40 14 2001 4349 4358
38. C.F. Hung, L. He, J. Juang, T.J. Lin, M. Ling, and T.C. Wu Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen J Virol 76 6 2002 2676 2682
39. T.W. Kim, C.F. Hung, J.W. Kim, J. Juang, P.J. Chen, and L. He Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity Hum Gene Ther 15 2 2004 167 177
40. S.C. Oliveira, J.S. Harms, R.R. Afonso, and G.A. Splitter A genetic immunization adjuvant system based on BVP22-antigen fusion Hum Gene Ther 12 10 2001 1353 1359
41. L.A. Kueltzo, N. Normand, P. O'Hare, and C.R. Middaugh Conformational lability of herpesvirus protein VP22 J Biol Chem 275 43 2000 33213 33221
42. Z. Lai, I. Han, G. Zirzow, R.O. Brady, and J. Reiser Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors Proc Natl Acad Sci USA 97 21 2000 11297 12302
43. D. Zavaglia, M.C. Favrot, B. Eymin, C. Tenaud, and J.L. Coll Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein Gene Ther 10 4 2003 314 325
44. A.M. Bennett, S.D. Perkins, and J.L. Holley DNA vaccination protects against botulinum neurotoxin type F Vaccine 21 23 2003 3110 3117
45. Z. You, X. Huang, J. Hester, H.C. Toh, and S.Y. Chen Targeting dendritic cells to enhance DNA vaccine potency Cancer Res 61 9 2001 3704 3711
46. J. Rice, C.A. King, M.B. Spellerberg, N. Fairweather, and F.K. Stevenson Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines Vaccine 17 23-24 1999 3030 3038
47. C.P. Locher, S.A. Witt, B.M. Ashlock, and J.A. Levy Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element DNA Cell Biol 21 8 2002 581 586
48. J.A. Leifert, and J.L. Whitton "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms Mol Ther 8 1 2003 13 20
49. J.A. Leifert, J.A. Lindencrona, J. Charo, and J.L. Whitton Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine Hum Gene Ther 12 15 2001 1881 1892
50. J.P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, and M.J. Gait Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake J Biol Chem 278 1 2003 585 590
51. M. Lundberg, S. Wikstrom, and M. Johansson Cell surface adherence and endocytosis of protein transduction domains Mol Ther 8 1 2003 143 150
52. D. Derossi, S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, and A. Prochiantz Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent J Biol Chem 271 30 1996 18188 18193
53. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, and K. Ueda Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery J Biol Chem 276 8 2001 5836 5840